BioSeek Licenses Two Novel Anti-Inflammatory Peptides
News Nov 14, 2008
BioSeek, Inc. announces that it has exclusively licensed two novel anti-inflammatory peptides from Amylin Pharmaceuticals, Inc.
The two novel peptides were identified as candidates for development by BioSeek as a result of an ongoing joint research collaboration initiated between the two companies in 2007. These two peptides will be the basis for proprietary optimization and development programs at BioSeek for potential indications outside of Amylin’s core therapeutic focus.
Under the collaboration, BioSeek applied its BioMAP® human biology screening systems to evaluate the potential of 500 peptides in Amylin’s proprietary polypeptide hormone library, PHORMOL™, to treat a range of inflammatory conditions.
From that pool of 500 peptides, BioSeek was granted the right to select and license two of the peptides for its own preclinical portfolio. In exchange for milestone payments and royalties payable to Amylin, BioSeek has the right to optimize, develop and outlicense the two selected peptides. BioSeek is also eligible to receive royalties if Amylin develops or licenses an additional limited set of peptides for uses identified in the collaboration.
“Exercising this license for two promising peptides from Amylin significantly expands our internal pipeline of drug candidates and demonstrates the broad utility of our BioMAP platform of predictive human biology screens to enhance and accelerate drug discovery,” said Michael C. Venuti, Ph.D., Chief Executive Officer of BioSeek.
“By generating predictive preclinical human data on the pharmacological properties of Amylin’s PHORMOL library, the BioMAP platform provided insight into the potential utility of the peptides across multiple therapeutic areas. We advanced this project rapidly to achieve the goal of identifying two promising anti-inflammatory peptides for BioSeek.”
The selection of two of the most promising lead peptides was guided by identification of dose-responsive anti-inflammatory activity across a broad panel of BioMAP systems.
BioSeek’s immediate objective is to bring these two peptides forward quickly through preclinical studies for both sequence optimization and pharmaceutical property improvements, with the intention of nominating preclinical candidates for further efficacy, toxicology and safety assessment.
More than 60 years after the drug thalidomide caused birth defects in thousands of children whose mothers took the drug while pregnant, scientists have solved a mystery that has lingered ever since the dangers of the drug first became apparent: how did the drug produce such severe fetal harm?READ MORE
Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent painful swellings of the skin and mucous membranes. A new drug has been developed to help prevent attacks of hereditary angioedema. It has now been investigated in an international study performed at over 26 university facilities in Europe, Canada and Australia.READ MORE